Tscan Therapeutics Inc TCRX

$0.15 +0.01 (4.21%)

Valuation

Market cap
9,672,000
Revenue TTM
$10,330,000
Net income TTM
$-129,770,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-1,256.24%
Debt to equity
0.87

Trading

Volume
391,700
Avg volume
597,016
Day's range
$0.14 – $0.16
Shares out
67,779,000
Stochastic %K
10%
Beta
1.21
Analysts
Hold
Price target
$3.50

Price

Company profile

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell t...

Show more

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
857 399 9500
Website
https://www.tscan.com
Address
830 Winter Street, Waltham, United States

Latest news

No headlines yet.

Stocktwits

ka1954 Nov 19, 10:34 PM
$TCRX 73m cash and 10m market cap. what the fuck is going on with this stock ? no rebound at all?
0 replies
saladman777 Nov 19, 1:29 PM
$TCRX why isn’t the management doing anything? No news or nothing? On paper, this is hella undervalued but that doesn’t matter if sentiment is trash and management do jack shit. Been waiting to jump into this for sometime but it just keeps finding new lows! What the fuck? Anyone still alive?
1 replies
Dailyfollower Nov 17, 12:35 AM 0 replies
Double_it_Helix Nov 15, 10:37 PM
$TCRX All 14 patients tracked in ALLOHA Cohort C showed complete donor chimerism at their last assessment.x
1 replies
pkbull Nov 13, 2:56 AM
$TCRX this is beyond ridiculous at this point. Most of the small caps are down everyday. Maybe one should only stick up the large caps when it comes to dip buying
0 replies
saladman777 Nov 12, 5:13 PM
$TCRX anyone still here? Is this bottom?
1 replies
d_risk Nov 12, 12:30 PM
$TCRX TScan Therapeutics, Inc. | 10Q Updated Risk Factors TScan says it has until Feb. 23, 2027 to regain compliance with Nasdaq’s minimum bid rule. Nasdaq could delist its stock if compliance is not restored. #RiskFactors #SECFilings 🟢 Added 🟠 Removed https://d-risk.ai/TCRX?filing=BzGhr9EqgwknqEsKt5Blg
0 replies
StocktwitsEarnings Nov 12, 12:07 PM
$TCRX Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.25 up 10.71% YoY • Reported revenue of $0.59M down -76.49% YoY • TScan Therapeutics believes existing cash resources will fund its current operating plan into the fourth quarter of 2027; no revenue, margin, or earnings guidance was provided.
0 replies